HMC
Harvard Management Company Portfolio holdings
AUM
$1.44B
This Quarter Return
+4.15%
1 Year Return
+33.17%
3 Year Return
+230.83%
5 Year Return
+163.57%
10 Year Return
+194.2%
AUM
$886M
AUM Growth
+$886M
(-13%)
Cap. Flow
-$156M
Cap. Flow
% of AUM
-17.64%
Top 10 Holdings %
Top 10 Hldgs %
96.5%
Holding
34
New
1
Increased
–
Reduced
4
Closed
12
Top Buys
| 1 |
Maplebear
CART
|
$15.4M |
Top Sells
| 1 |
Alphabet (Google) Class A
GOOGL
|
$88M |
| 2 |
Meta Platforms (Facebook)
META
|
$53.3M |
| 3 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
$7.17M |
| 4 |
Recursion Pharmaceuticals
RXRX
|
$6.59M |
| 5 |
Nurix Therapeutics
NRIX
|
$3.14M |
Sector Composition
| 1 | Communication Services | 58.17% |
| 2 | Consumer Discretionary | 23.31% |
| 3 | Technology | 13.87% |
| 4 | Healthcare | 2.34% |
| 5 | Industrials | 0.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Nurix Therapeutics
NRIX
$714M
| – | – | -314,762 | Closed | -$3.14M |
|
27
Pacific Biosciences
PACB
$393M
| – | – | -233,186 | Closed | -$3.1M |
|
28
Praxis Precision Medicines
PRAX
$958M
| – | – | -692,617 | Closed | -$797K |
|
|
29
Recursion Pharmaceuticals
RXRX
$2.04B
| – | – | -882,129 | Closed | -$6.59M |
|
|
KNTE
30
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| – | – | -462,418 | Closed | -$1.4M |
|
|
EQRX
31
DELISTED
EQRx, Inc. Common Stock
EQRX
| – | – | -3,853,367 | Closed | -$7.17M |
|
|
DBTX
32
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| – | – | -326,029 | Closed | -$1.26M |
|
|
PRDS
33
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| – | – | -400,000 | Closed | -$724K |
|
34
Dianthus Therapeutics
DNTH
$759M
| – | – | -332,610 | Closed | -$252K |
|